CFSAN priorities
This article was originally published in The Rose Sheet
Executive Summary
Revitalization of FDA's cosmetics program cited among Center for Food Safety and Applied Nutrition's fiscal 2003 program priority accomplishments. Office of Cosmetics & Colors met with stakeholders to gain input on revitalization efforts, and as a result, the office has "developed priority activities that will be highlighted and implemented in CFSAN's FY 2004 program priorities," the center announces in its year-end "report card," released Nov. 24. Development of a Web-based voluntary cosmetic registration program, draft labeling guidance for cosmetics containing alpha hydroxy acids also cited as program accomplishments. Likewise, the office analyzed all color additive batches and determined certification status in an average of five working days, FDA adds. During the year, CFSAN completed 92% of its "A" list priorities, with the majority focused on bioterrorism and food safety initiatives...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.